Shares of Alembic Pharmaceuticals Limited plummeted by more than 9% on Monday following the company’s announcement of weaker-than-anticipated earnings for the March 2026 quarter. This decline was primarily attributed to a decrease in operating margins, which negatively impacted investor confidence. The stock hit an intra-day low of Rs 710.70 on the National Stock Exchange of India (NSE).
At the close of trading, the shares were down by 7.42% or Rs 58.20 at Rs 725.90. Year-to-date, the stock has experienced a decline of approximately 7%. Alembic Pharmaceuticals’ market capitalization currently stands at Rs 14,142 crore. The stock has reached a 52-week high of Rs 1,107.90 and a 52-week low of Rs 635.80.
In the fourth quarter of FY26, Alembic Pharmaceuticals reported a 29% year-on-year increase in consolidated net profit, amounting to Rs 202 crore compared to Rs 157 crore in the same period the previous fiscal year. Despite this growth, the company’s operating performance weakened during the quarter. EBITDA fell by 16.2% year-on-year to Rs 228 crore from Rs 272 crore, with the EBITDA margin shrinking significantly to 12.3% from 15.4% in the corresponding period last fiscal year.
The company’s India-branded business saw a 4% year-on-year growth to Rs 568 crore in the quarter, driven by expansions in gynaecology, gastrology, ophthalmology, and animal healthcare segments. Additionally, Alembic introduced two new products in the domestic market during this period. The international business of the company rose by 11% year-on-year to Rs 564 crore, primarily due to the US formulations business.
Throughout the quarter, Alembic launched six products in the US market, while revenue from the ex-US generics business amounted to Rs 369 crore. The company also secured four ANDA approvals during the same period.
